Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2007 1
2012 2
2013 1
2014 2
2015 1
2016 5
2017 5
2018 8
2019 12
2020 5
2021 10
2022 5
2023 16
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for m kalantari
Your search for M Kalantarii retrieved no results
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Maurer MS, et al. N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757. N Engl J Med. 2023. PMID: 37888916 Free PMC article. Clinical Trial.
At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran gr …
At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate o …
Concurrent of blaCTX-M and blaNDM-1 genes in clinical isolates of Escherichia coli from northern Iran.
Shahandeh Z, Kalantari N, Sadighian F, Aram H, Etminan M. Shahandeh Z, et al. Trop Biomed. 2019 Jun 1;36(2):459-467. Trop Biomed. 2019. PMID: 33597407 Free article.
The ESBLs and MBLs positive isolates were analysed for the existence of blaCTX-M, blaTEM, blaSHV, blaNDM-1 and blaIMP-1 genes with the conventional PCR method. ...PCR analysis showed that the predominant genes were blaCTX-M15(95.5%) and blaNDM-1 (31.9%) among ESBL and MBL …
The ESBLs and MBLs positive isolates were analysed for the existence of blaCTX-M, blaTEM, blaSHV, blaNDM-1 and blaIMP-1 genes with th …
Clinical Manifestations, Immunological Characteristics and Genetic Analysis of Patients with Hyper-Immunoglobulin M Syndrome in Iran.
Tafakori Delbari M, Cheraghi T, Yazdani R, Fekrvand S, Delavari S, Azizi G, Chavoshzadeh Z, Mahdaviani SA, Ahanchian H, Khoshkhui M, Behmanesh F, Aleyasin S, Esmaeilzadeh H, Jabbari-Azad F, Fallahpour M, Zamani M, Madani SP, Moazzami B, Habibi S, Rezaei A, Lotfalikhani A, Movahed M, Shariat M, Kalantari A, Babaei D, Darabi M, Parvaneh N, Rezaei N, Abolhassani H, Aghamohammadi A. Tafakori Delbari M, et al. Int Arch Allergy Immunol. 2019;180(1):52-63. doi: 10.1159/000500197. Epub 2019 May 22. Int Arch Allergy Immunol. 2019. PMID: 31117086
BACKGROUND: Hyper-immunoglobulin M (HIGM) syndrome is a rare heterogeneous group of primary immunodeficiency disorders characterized by low or absent serum levels of IgG and IgA along with normal or elevated serum levels of IgM. ...
BACKGROUND: Hyper-immunoglobulin M (HIGM) syndrome is a rare heterogeneous group of primary immunodeficiency disorders characterized …
Improvement in Biventricular Cardiac Function After Ambulatory Counterpulsation.
Imamura T, Juricek C, Song T, Ota T, Onsager D, Sarswat N, Kim G, Raikhelkar J, Kalantari S, Sayer G, Burkhoff D, Jeevanandam V, Uriel N. Imamura T, et al. J Card Fail. 2019 Jan;25(1):20-26. doi: 10.1016/j.cardfail.2018.11.001. Epub 2018 Nov 8. J Card Fail. 2019. PMID: 30415014

At 30 days, there was a significant improvement in left ventricular ejection fraction (16.5% 11.9% vs 24.4% 12.8%; P = .007) and marked reduction in left atrial size (62.7 35.7 mL/m(2) vs 33.8 17.2 mL/m(2); P < .001). Right ventricular fractional area change impr

…
At 30 days, there was a significant improvement in left ventricular ejection fraction (16.5% 11.9% vs 24.4% 12.8%; P = .007) and marked redu …
67 results